Serum enolase: a non-destructive biomarker of white skeletal myopathy during pancreas disease (PD) in Atlantic salmon Salmo salar L.

Diseases which cause skeletal muscle myopathy are some of the most economically damaging diseases in Atlantic salmon, Salmo salar L., aquaculture. Despite this, there are limited means of assessing fish health non-destructively. Previous investigation of the serum proteome of Atlantic salmon, Salmo...

Full description

Bibliographic Details
Published in:Journal of Fish Diseases
Main Authors: Braceland, M., McLoughlin, M.F., Tinsley, J., Wallace, C., Cockerill, D., McLaughlin, M., Eckersall, P.D.
Format: Article in Journal/Newspaper
Language:English
Published: Wiley 2015
Subjects:
Atlantic salmon
Salmo salar
Online Access:https://eprints.gla.ac.uk/100072/
https://eprints.gla.ac.uk/100072/1/100072.pdf
Description
Summary:Diseases which cause skeletal muscle myopathy are some of the most economically damaging diseases in Atlantic salmon, Salmo salar L., aquaculture. Despite this, there are limited means of assessing fish health non-destructively. Previous investigation of the serum proteome of Atlantic salmon, Salmo salar L., during pancreas disease (PD) has identified proteins in serum that have potential as biomarkers of the disease. Amongst these proteins, the enzyme enolase was selected as the most viable for use as a biomarker of muscle myopathy associated with PD. Western blot and immunoassay (ELISA) validated enolase as a biomarker for PD, whilst immunohistochemistry identified white muscle as the source of enolase. Enolase was shown to be a specific marker for white muscle myopathy in salmon, rising in serum concentration significantly correlating with pathological damage to the tissue.

Similar Items